Gilead Sciences has now formally closed its previously disclosed deal to acquire Tubulis GmbH, the Germany-based clinical-stage biopharmaceutical company dedicated to developing the next...
Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...
Gilead Sciences, Inc. announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy for the treatment of...
